Vident Advisory’s Dr. Reddy's Laboratories RDY Stock Holding History

Vident Advisory’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71M	Sell	187,312 -30,269	-14%	-$408K	0.02%	574
2026 Q1	$3.01M	Buy	217,581 +8,834	+4%	+$123K	0.03%	500
2025 Q4	$2.93M	Buy	208,747 +15,686	+8%	+$220K	0.03%	459
2025 Q3	$2.7M	Buy	193,061 +3,792	+2%	+$54.6K	0.03%	471
2025 Q2	$2.84M	Buy	189,269 +29,242	+18%	+$418K	0.03%	409
2025 Q1	$2.11M	Buy	160,027 +8,696	+6%	+$120K	0.03%	468
2024 Q4	$2.39M	Buy	151,331 +32,266	+27%	+$485K	0.04%	374
2024 Q3	$1.89M	Buy	119,065 +310	+0.3%	+$4.99K	0.05%	405
2024 Q2	$1.81M	Buy	118,755 +4,050	+4%	+$58K	0.05%	405
2024 Q1	$1.68M	Buy	114,705 +4,090	+4%	+$59.7K	0.04%	420
2023 Q4	$1.54M	Buy	110,615 +14,810	+15%	+$198K	0.04%	446
2023 Q3	$1.28M	Buy	+95,805	New	+$1.3M	0.04%	442

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vident Advisory's RDY Position: Q2 2026 in Review

Vident Advisory reduced its Dr. Reddy's Laboratories (RDY) stake by 14% in Q2 2026, selling an estimated $408K and leaving 187,312 shares worth $2.71M. The position accounts for 0.02% of the portfolio, ranked #574.

Vident Advisory first reported a position in RDY in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.01M in Q1 2026. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

Vident Advisory held 187,312 shares of Dr. Reddy's Laboratories worth $2.71M as of Q2 2026.
Vident Advisory sold 30,269 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $408K.
Dr. Reddy's Laboratories made up 0.02% of Vident Advisory's portfolio in Q2 2026, its #574 holding.
Vident Advisory first reported a position in Dr. Reddy's Laboratories in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's Dr. Reddy's Laboratories position peaked at $3.01M in Q1 2026.
238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.